Managing Injection Site Reactions on Wegovy: The HealthRX.com Step-by-Step Protocol

At a glance

• Incidence: 3.2% in the STEP 1 key trial (vs. 1.4% placebo)
• Typical onset: Minutes to 24 hours post-injection
• Duration: Most reactions resolve within 48 to 72 hours without treatment
• First-line management: Site rotation, cold compress, correct injection technique
• Escalate if: Induration >5 cm, symptoms lasting >72 hours, fever, spreading erythema, or recurrence at every injection
• Discontinue if: Anaphylaxis, generalized urticaria, angioedema, or confirmed mast-cell-mediated allergy on testing

Why Wegovy Causes Injection Site Reactions

Subcutaneous semaglutide triggers a localized response through two overlapping mechanisms. First, the needle itself causes mechanical disruption of dermal and subdermal tissue, which activates resident mast cells and releases histamine into surrounding capillary beds. Second, the drug formulation (semaglutide in a phosphate buffer at pH 7.4) can provoke low-grade irritation as it disperses through the subcutaneous space. The Wegovy prescribing information lists erythema, pain, and pruritus as the most common local manifestations. These are pharmacologically distinct from true IgE-mediated allergy, which occurs in fewer than 0.1% of patients across the STEP program.

The dose-escalation schedule may also play a role. During the STEP 3 trial, local reactions were more common during the 1.7 mg and 2.4 mg phases than at the 0.25 mg starting dose, suggesting a volume- or concentration-dependent component to local tissue irritation.

Step 1: Assess the Reaction

Before intervening, characterize what you are seeing. Grab a ruler or use your fingertip (roughly 1.5 cm wide) as a reference.

Measure and document:

• Diameter of erythema (in centimeters)
• Presence of induration (a firm, raised area under the skin)
• Associated symptoms: itching, warmth, pain on palpation, bruising
• Time from injection to symptom onset

Grade the reaction using a modified Common Terminology Criteria (CTCAE v5.0) scale:

| Grade | Presentation | Action | |-------|-------------|--------| | 1 | Painless erythema <2 cm, no induration | Observe only | | 2 | Tender erythema 2 to 5 cm, mild induration | First-line interventions (Step 2) | | 3 | Erythema >5 cm, significant induration, pain limiting daily activity | Escalate (Step 4) | | 4 | Necrosis, ulceration, or systemic signs | Discontinue and refer urgently |

Most Wegovy injection site reactions fall into Grade 1 or 2. In the STEP 1 trial, no Grade 4 events were reported in the semaglutide arm, and discontinuation for injection site reactions was exceedingly rare (<0.1%).

Step 2: First-Line Interventions

For Grade 1 and Grade 2 reactions, these non-pharmacological measures resolve the majority of cases.

Injection technique review. Per the Novo Nordisk Wegovy FlexTouch instructions, confirm the patient is:

• Injecting into the abdomen (at least 5 cm from the navel), thigh, or upper arm
• Pinching a skin fold before insertion at a 90-degree angle
• Holding the pen in place for at least 6 seconds after the dose counter returns to zero
• Allowing the solution to reach room temperature (15 to 30 minutes out of refrigeration) before injection

Site rotation. Use a systematic rotation pattern. The American Diabetes Association injection guidance recommends dividing each anatomical region into quadrants and moving clockwise weekly. Since Wegovy is once-weekly, patients can rotate among four sites on a monthly cycle, keeping injections at least 2 to 3 cm apart from previous puncture points.

Cold compress. Apply a cloth-wrapped ice pack to the site for 10 to 15 minutes immediately after injection. Cold-induced vasoconstriction reduces histamine-mediated erythema and edema. A randomized trial of cold application in subcutaneous injections demonstrated significant reductions in pain, bruising, and local induration when ice was applied pre- and post-injection.

Step 3: Second-Line Pharmacological Options

If first-line measures do not control symptoms after two consecutive injection cycles, add targeted pharmacotherapy.

Oral antihistamines. A non-sedating H1 blocker such as cetirizine 10 mg or loratadine 10 mg taken 30 to 60 minutes before the injection can blunt the local histamine response. The EAACI/GA2LEN guidelines on urticaria management support second-generation antihistamines as first-line for histamine-driven skin reactions, and these agents are well tolerated alongside GLP-1 receptor agonists with no known drug interactions per the Wegovy prescribing label.

Topical corticosteroids. For persistent erythema or pruritus at the injection site, a mid-potency topical steroid (triamcinolone 0.1% cream) applied twice daily for 3 to 5 days can reduce inflammation. Avoid applying the steroid before the next injection to prevent altered drug absorption.

Needle gauge consideration. The Wegovy FlexTouch pen uses a fixed pre-attached needle system. However, patients who previously used pen needles with other GLP-1 therapies and experienced fewer reactions may discuss this history with their prescriber. Thinner gauge needles (32G vs. 30G) have been associated with reduced injection pain in insulin studies, and this principle applies broadly to subcutaneous delivery.

Step 4: When to Escalate

Escalate to your prescriber or care team if any of the following occur:

• Erythema or induration exceeding 5 cm that does not improve within 72 hours
• Reactions worsening with each successive injection despite technique optimization
• Development of subcutaneous nodules that persist beyond two weeks
• Satellite lesions (erythema spreading beyond the immediate injection zone)
• Any systemic symptom: fever, generalized rash, joint pain, or difficulty breathing

Persistent nodules may represent granulomatous reactions. A case series published in the Journal of the American Academy of Dermatology documented localized granulomas at GLP-1 agonist injection sites, which required biopsy for definitive diagnosis and occasionally warranted drug discontinuation.

Your prescriber may order:

• Punch biopsy of a persistent nodule to rule out granulomatous or vasculitic pathology
• Serum tryptase if mast cell activation is suspected
• Referral to allergy/immunology for skin prick testing if anaphylactoid features are present

Step 5: Defining Success and Failure

Success looks like:

• Reactions downgraded from Grade 2 to Grade 1 (or absent) within two injection cycles of implementing first-line measures
• Patient can self-inject weekly without significant discomfort or anxiety
• No need for routine pre-medication beyond the initial optimization period

Failure looks like:

• Persistent Grade 2 or higher reactions despite two full cycles of technique review, rotation, cold compress, and oral antihistamine pre-treatment
• Patient requests to discontinue due to injection site discomfort
• Development of Grade 3 or 4 features at any point

If the protocol fails, the STEP 4 trial showed that patients who discontinued semaglutide regained weight rapidly, so the clinical decision involves weighing injection site tolerability against metabolic benefit. Your prescriber may consider switching to oral semaglutide (Rybelsus), which eliminates the subcutaneous route entirely, or to tirzepatide (Zepbound), which uses a different formulation and delivery device that some patients tolerate better.

Special Populations

Patients on anticoagulants. Warfarin, apixaban, or other blood thinners increase bruising risk at the injection site. Per anticoagulation management guidelines, applying firm pressure for 30 to 60 seconds post-injection (without rubbing) reduces hematoma formation. Do not confuse bruising with an allergic reaction.

Patients with dermatologic conditions. Those with eczema, psoriasis, or chronic urticaria may experience exaggerated local responses. Avoid injecting into active plaques or lesions. A review of subcutaneous injection practices in dermatologic patients recommends choosing unaffected skin and expanding the rotation map to include all three approved anatomical sites.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. STEP 1 trial
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight. JAMA. 2021;325(14):1403-1413. STEP 3 trial
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425. STEP 4 trial
• Novo Nordisk. Wegovy (semaglutide) injection prescribing information. FDA label
• Novo Nordisk. Wegovy FlexTouch pen instructions for use. Novo Nordisk PI
• Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Clin Diabetes. 2022;40(2):161-170. ADA injection guidance
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014;69(7):868-887. EAACI guidelines
• Aggarwal P, Lens MB. Injection site reactions with subcutaneous biological therapies. J Am Acad Dermatol. 2022. JAAD case series
• Beirne PV, Hennessy S, Cadogan SL, et al. Needle size for vaccination procedures in children and adolescents. Cochrane Database Syst Rev. 2018. Needle gauge and pain
• Şendir M, Büyükyılmaz F, Çelik Z, Taşköprü İ. Comparison of subcutaneous injection pain with cold application. Pain Manag Nurs. 2015;16(3):328-335. Cold application RCT
• US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. NCI CTCAE